As such targeting LILRB4 expressing cells for destruction, such as with a CAR-T product or antibody drug conjugate, would selectively deplete the MPS allowing for preservation of the CAR-T and treatment of established CRS/ICANS [80, 85]. The gene discussed is LILRB4; the disease is congenital rubella syndrome.